Hemispherx Biopharma's International Team of Clinical Researchers to Present New Data on Experimental Treatment of CFS.Business Editors & Health/Medical Writers BIOWIRE2K PHILADELPHIA--(BUSINESS WIRE)--Jan. 15, 2003 "Expanded Access Expanded access refers to the inclusion of patients in a clinical trial for a new therapeutic treatment or chemical entity, where those patients would not satisfy the enrolment criteria for the scientific study in progress. " Program with Ampligen(R) Includes 10 Treatment Centers in USA Hemispherx Biopharma Inc. (Amex: HEB HEB Hebrew HEB Hurst-Euless-Bedford (Texas) HEB Hot Electron Bolometer HEB Hindu Endowments Board (Singapore) HEB Here Everything's Better HEB High-Energy Beam HEB High Energy Biscuit ) reported that a team of clinical researchers would report new data on the experimental immunotherapeutic, Ampligen(R), at the upcoming 6th International Research and Clinical Conference of the American Association for CFS CFS abbr. chronic fatigue syndrome CFS, n.pr See syndrome, chronic fatigue. CFS Chronic fatigue syndrome, see there (Chronic Fatigue Syndrome chronic fatigue syndrome (CFS), collection of persistent, debilitating symptoms, the most notable of which is severe, lasting fatigue. In other countries it is known variously as myalgic encephalomyelitis, chronic fatigue and immune dysfunction syndrome, and ). The presentation entitled "Ampligen(R) Treatment of Patients with Chronic Fatigue Syndrome (CFS) Under an Expanded Access Program" is scheduled for Friday, January 31, 2003, in Chantilly, VA and will evaluate various parameters of physical performance and quality of life in severely debilitated de·bil·i·tat·ed adj. Showing impairment of energy or strength; enfeebled. See Synonyms at weak. Adj. 1. debilitated - lacking strength or vigor asthenic, enervated, adynamic CFS patients. The clinical research team is supported by an internationally recognized group of "basic" researchers from both the USA and Europe, in partnership with Hemispherx, who are determining mechanisms of disease etiology and potential therapeutic intervention in severe forms of CFS. More information on the conference can be obtained from internet sites: aacfs.org/html/conf2003toc.htm and on Hemispherx's comprehensive clinical trials at www.hemispherx.net. About Hemispherx Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. (NA) class for chronic viral diseases and disorders of the Immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. including, HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information please visit the company's Website at www.hemispherx.net. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion